Serum Levels of IL-6 and TNF-alpha Correlate with Clinicopathological Features and Patient Survival in Patients with Prostate Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2004 May 20

PMID 15150588

Citations 171

Authors

V Michalaki

K Syrigos

P Charles

J Waxman

Affiliations

Soon will be listed here.

Abstract

Interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) are important multifunctional cytokines involved in tumour growth and metastasis. In this study, we have measured serial levels of serum IL-6 and TNF-alpha in prostate cancer patients. A total of 80 patients with carcinoma of the prostate and 38 controls were studied. Three patient groups, with small bulk localised, large volume localised and metastatic prostate cancer, were assessed. Serum IL-6 and TNF-alpha levels were measured and correlated with clinicopathological variables and patient survival. Serial changes in these cytokines were also assessed and related to disease progression in 40 patients with recurrent prostate cancer. Serum IL-6 levels in patients with metastatic disease (9.3+/-7.8 pg x ml(-1)) were higher than those in patients with localised disease (1.3+/-0.8 pg x ml(-1), P<0.001). Significantly elevated levels of TNF-alpha were found in metastatic disease (6.3+/-3.6 pg x ml(-1)) compared with localised disease (1.1+/-0.5 pg x ml(-1), P<0.001). The levels of both cytokines were directly correlated with the extent of the disease. Serial analysis in 40 patients with recurrent tumours showed that both cytokines became elevated at the point of prostate-specific antigen progression. In conclusion, these results suggest that IL-6 and TNF-alpha correlate with the extent of disease in patients with prostate cancer and may be monitored in conjunction with other disease markers.

Citing Articles

Association between triglyceride‑glucose index as a marker of insulin resistance and the risk of malignant melanoma: A retrospective study.

Sun J, Han Z, Song C Oncol Lett. 2025; 29(4):173.

PMID: 39968015 PMC: 11834148. DOI: 10.3892/ol.2025.14919.

Serum cardiac and inflammatory biomarker levels following chemotherapy among female patients with breast cancer attending at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.

Getie M, Mekonnen B, Seifu D, Mulugeta Y, Tebeje S, Tafere C BMC Cancer. 2025; 25(1):175.

PMID: 39885469 PMC: 11783745. DOI: 10.1186/s12885-025-13583-5.

IL6 and IL6R as Prognostic Biomarkers in Colorectal Cancer.

Pennel K, Kurniawan A, Samir Foad Al-Badran S, Schubert Santana L, Quinn J, Nixon C Biomolecules. 2025; 14(12.

PMID: 39766336 PMC: 11727588. DOI: 10.3390/biom14121629.

Assessment of Vitamin E and Glutathione Peroxidase Levels in Salivary Samples of Children With and Without Dental Caries in Erbil City, Iraq.

Hussein P, Hussein V Cureus. 2025; 16(11):e74872.

PMID: 39741611 PMC: 11685327. DOI: 10.7759/cureus.74872.

Causal association of peripheral immune cell counts with risk of prostate cancer: insights from bidirectional Mendelian randomization.

Ren X, Zhang L, Wang K, Li F Front Oncol. 2024; 14:1374927.

PMID: 39678517 PMC: 11638012. DOI: 10.3389/fonc.2024.1374927.

References

Spiotto M, Chung T . STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate. 2000; 42(2):88-98. DOI: 10.1002/(sici)1097-0045(20000201)42:2<88::aid-pros2>3.0.co;2-p. View

Huss W, Barrios R, Foster B, Greenberg N . Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate. 2002; 54(1):8-16. DOI: 10.1002/pros.10163. View

Smith P, Hobisch A, Lin D, Culig Z, Keller E . Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 2001; 12(1):33-40. DOI: 10.1016/s1359-6101(00)00021-6. View

Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R . Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer. 2002; 86(9):1396-400. PMC: 2375361. DOI: 10.1038/sj.bjc.6600257. View

Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H . Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000; 6(7):2702-6. View

Smith D, Catalona W, Herschman J . Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996; 276(16):1309-15. View

Deeble P, Murphy D, Parsons S, Cox M . Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol. 2001; 21(24):8471-82. PMC: 100010. DOI: 10.1128/MCB.21.24.8471-8482.2001. View

Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A . Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995; 71(2):354-6. PMC: 2033591. DOI: 10.1038/bjc.1995.71. View

Muenchen H, Lin D, Walsh M, Keller E, Pienta K . Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". Clin Cancer Res. 2000; 6(5):1969-77. View

10.

Twillie D, Eisenberger M, Carducci M, Hseih W, Kim W, Simons J . Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology. 1995; 45(3):542-9. DOI: 10.1016/S0090-4295(99)80034-X. View

11.

Lou W, Ni Z, Dyer K, Tweardy D, Gao A . Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway . Prostate. 2000; 42(3):239-42. DOI: 10.1002/(sici)1097-0045(20000215)42:3<239::aid-pros10>3.0.co;2-g. View

12.

Mizokami A, Gotoh A, Yamada H, Keller E, Matsumoto T . Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol. 2000; 164(3 Pt 1):800-5. DOI: 10.1097/00005392-200009010-00053. View

13.

Drachenberg D, Elgamal A, Rowbotham R, Peterson M, Murphy G . Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 1999; 41(2):127-33. DOI: 10.1002/(sici)1097-0045(19991001)41:2<127::aid-pros7>3.0.co;2-h. View

14.

De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G . Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep. 1998; 5(3):649-52. View

15.

Wise G, Marella V, Talluri G, Shirazian D . Cytokine variations in patients with hormone treated prostate cancer. J Urol. 2000; 164(3 Pt 1):722-5. DOI: 10.1097/00005392-200009010-00024. View

16.

Adler H, McCurdy M, Kattan M, Timme T, Scardino P, Thompson T . Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999; 161(1):182-7. View

17.

Hobisch A, Eder I, Putz T, Horninger W, Bartsch G, Klocker H . Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998; 58(20):4640-5. View

18.

Blay J, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y . Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992; 52(12):3317-22. View

19.

Bok R, Small E . Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer. 2002; 2(12):918-26. DOI: 10.1038/nrc951. View

20.

Chen T, Wang L, Farrar W . Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 2000; 60(8):2132-5. View